Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Raw Materials (2019 - 2025)

Aytu Biopharma (AYTU) has disclosed Raw Materials for 7 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Raw Materials rose 144.94% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 million, a 144.94% increase, with the full-year FY2025 number at $1.1 million, up 319.17% from a year prior.
  • Raw Materials was $1.2 million for Q4 2025 at Aytu Biopharma, down from $1.4 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $2.6 million in Q3 2021 to a low of $266000.0 in Q2 2024.
  • A 5-year average of $1.6 million and a median of $1.8 million in 2022 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: skyrocketed 471.54% in 2021, then crashed 79.55% in 2024.
  • Aytu Biopharma's Raw Materials stood at $2.4 million in 2021, then dropped by 26.41% to $1.8 million in 2022, then dropped by 7.39% to $1.7 million in 2023, then crashed by 70.13% to $494000.0 in 2024, then soared by 144.94% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Raw Materials are $1.2 million (Q4 2025), $1.4 million (Q3 2025), and $1.1 million (Q2 2025).